This study involves people with Chronic Obstructive Pulmonary Disease, which is a long-term lung condition that makes breathing difficult and affects the airways. The study will test two vaccines that protect against different types of infections that can affect the lungs. The first vaccine is Arexvy, which protects against Respiratory Syncytial Virus, a common virus that can cause serious breathing problems, especially in older adults and people with lung disease. The second vaccine is Prevenar 20, which protects against bacteria called pneumococcus that can cause lung infections and other serious illnesses. The study will also use a placebo, which is a substance that looks like the vaccine but contains no active ingredients.
The purpose of the study is to find out if the Arexvy vaccine can strengthen the body’s natural defense system in people with lung disease who are at higher risk for severe breathing infections. The researchers want to see if giving Arexvy can help the body respond better to the Prevenar 20 vaccine when they are given at the same time or close together. They will also look at whether Arexvy provides broader protection against various breathing infections and helps control viruses that may stay in the body for a long time.
Participants in this study will receive injections of the vaccines in their arm muscle. Some people will get both vaccines at the same time, while others will receive them at different times. The study will involve blood sample collections at different time points to measure how well the immune system, which is the body’s defense against infections, responds to the vaccines. The researchers will look at specific markers in the blood that show how active the immune system is and measure the levels of protective proteins called antibodies that the body makes after vaccination. The study will follow participants for several months after they receive the vaccines to see how long the protection lasts.
Denmark 
